Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 47 to 55 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Nutritional-GICompleted with results
ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding
, protocol number Alcresta 0000498
This open label study is taking place at multiple care centres across the US. It will look at the safety, tolerability and effectiveness of Relizorb, a new digestive enzyme cartridge for people using enteral tube feedings.
4 Years and Older
No Mutation Requirement
Less than 100%
Number of Visits:
Length of Participation:
SOLUTION: Study of Liprotamase in people with CF
, protocol number NCT00449878 AN-EP13331 - Anthera
This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug Liprotamase in people with CF who are currently taking digestive enzymes.
7 Years and Older
30% or greater
SIMPLICITY: Phase 3 study of liprotamase in people with CF-related pancreatic insufficiency
, protocol number Anthera AN-EP13332
This two-part study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of a new, water-soluble formulation of liprotamase.
28 Days to 17 Years
No FEV1 Limit
Anti-InflammatoryCompleted with results
AquADEKs-2: Effects of an antioxidant-enriched multivitamin on inflammation and oxidative stress in people with CF
, protocol number AquADECKs-IP-12
This study took place at multiple care centres across the US. It looked at the effects on an anti-oxidant enriched multivitamin supplement on inflammation and oxidative stress in people with CF.
10 Years and Older
40 to 100%
ObservationalCompleted with results
BONUS: Baby Observational and Nutritional Study
, protocol number BONUS-IP-11, BONUS10K0
This study took place at multiple care centres across the US. It aimed to gain a better understanding of the factors that interfere with good growth in infants with CF.
Less than 15 weeks
Anti-InfectiveCompleted with results
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis
, protocol number Novartis CTBM100C2401
This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
6 Years and Older
25 to 75%
Anti-InfectiveClosed to enrollment
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study
, protocol number Novartis CTBM100C2401E1
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
25 to 75%
Phase 4 TOBI Podhaler observational study
, protocol number Novartis CTBM100C2407
This study is taking place at multiple care centres across the US. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.
25 to 80%
TOBI Podhaler Usability Study
, protocol number Novartis CTBM100C2412
This study took place at multiple care centres across the US. It looked at how well people are able to understand and follow the TOBI Podhaler instructions for use.
25% or greater
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled
, protocol number Novartis CTBM100CUS03
This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.